Overview

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
Phase:
Early Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Treatments:
Avelumab
Cemiplimab
Immune Checkpoint Inhibitors
Ipilimumab
Pembrolizumab